OLD AYALA, INC
AYLA evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Lead Asset:
- adxs-her2 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for AYLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
adxs-her2 (Phase 1)
Next Catalyst
—
Tracking 5 pipeline candidates for OLD AYALA, INC.
Run OLD AYALA, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OLD AYALA, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is OLD AYALA, INC's lead drug candidate?
OLD AYALA, INC's most advanced tracked candidate is adxs-her2 (Phase 1) for HER2 expressing solid tumors (osteosarcoma).
Who is the CEO of OLD AYALA, INC?
Roni Mamluk, Ph.D. is the chief executive officer of OLD AYALA, INC (AYLA).
What therapeutic areas does OLD AYALA, INC focus on?
OLD AYALA, INC develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.